Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, announced a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress in Rome, Italy, from October 22-25, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion.
The presentation, titled 'High-efficiency homology-directed insertion into the genome using engineered homing endonucleases', will be delivered by Dr. Adam Mischler, Senior Scientist at Precision BioSciences Gene Discovery. The poster (Number #PO678) will be presented on Thursday, October 24, 2024, from 6:00-7:30pm CEST. This presentation highlights Precision BioSciences' advancements in gene editing technology, particularly in addressing diseases where a defective gene requires the expression of a new DNA sequence.
Precision BioSciences (Nasdaq: DTIL), un'azienda avanzata nel settore dell'editing genetico, ha annunciato una presentazione poster al 31° Congresso Annuale della Società Europea di Genetica e Terapia Cellulare (ESGCT) che si svolgerà a Roma, Italia, dal 22 al 25 ottobre 2024. L'azienda utilizza la sua piattaforma proprietaria ARCUS® per sviluppare terapie di editing genetico in vivo per modifiche genetiche sofisticate, inclusa l'inserzione di geni.
La presentazione, intitolata 'Inserzione ad alta efficienza diretta per omologia nel genoma usando endonucleasi di homing ingegnerizzate', sarà tenuta dal Dr. Adam Mischler, Scienziato Senior presso Precision BioSciences Gene Discovery. Il poster (Numero #PO678) sarà presentato giovedì 24 ottobre 2024, dalle 18:00 alle 19:30 CEST. Questa presentazione mette in risalto i progressi di Precision BioSciences nella tecnologia di editing genetico, in particolare nel trattamento di malattie in cui un gene difettoso richiede l'espressione di una nuova sequenza di DNA.
Precision BioSciences (Nasdaq: DTIL), una empresa avanzada en edición genética, anunció una presentación de póster en el 31° Congreso Anual de la Sociedad Europea de Terapia Génica y Celular (ESGCT) que se llevará a cabo en Roma, Italia, del 22 al 25 de octubre de 2024. La empresa utiliza su plataforma propietaria ARCUS® para desarrollar terapias de edición genética in vivo para ediciones genéticas sofisticadas, incluida la inserción de genes.
La presentación, titulada 'Inserción dirigida por homología de alta eficiencia en el genoma utilizando endonucleasas de homing ingenierizadas', será impartida por el Dr. Adam Mischler, Científico Senior en Precision BioSciences Gene Discovery. El póster (Número #PO678) se presentará el jueves 24 de octubre de 2024, de 18:00 a 19:30 CEST. Esta presentación destaca los avances de Precision BioSciences en la tecnología de edición genética, particularmente en el abordaje de enfermedades donde un gen defectuoso requiere la expresión de una nueva secuencia de ADN.
프리시전 바이오사이언스 (Nasdaq: DTIL), 첨단 유전자 편집 회사는 2024년 10월 22일부터 25일까지 이탈리아 로마에서 열리는 제31회 유럽 유전자 및 세포 치료 학회(ESGCT)에서 포스터 발표를 발표한다고 발표했습니다. 이 회사는 고유의 ARCUS® 플랫폼을 활용하여 유전자 삽입을 포함한 복잡한 유전자 편집을 위한 인 비보 유전자 편집 치료법을 개발합니다.
발표 제목은 '공학적 호밍 엔도뉴클레아제를 이용한 유전체 내 고효율 동질염기서열 삽입'이며, 프리시전 바이오사이언스 유전자 발견의 수석 과학자 Adam Mischler 박사가 발표합니다. 포스터(번호 #PO678)는 2024년 10월 24일 목요일, 오후 6시에서 7시 30분 CEST까지 발표됩니다. 이 발표는 결함이 있는 유전자가 새로운 DNA 서열의 발현을 요구하는 질병을 해결하는 데 특히 유효한 프리시전 바이오사이언스의 유전자 편집 기술의 발전을 강조합니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise de pointe dans le domaine de l'édition génétique, a annoncé une présentation de poster lors du 31e Congrès Annuel de la Société Européenne de Thérapie Génétique et Cellulaire (ESGCT) qui se tiendra à Rome, en Italie, du 22 au 25 octobre 2024. L'entreprise utilise sa plateforme propriétaire ARCUS® pour développer des thérapies d'édition génétique in vivo pour des modifications génétiques complexes, y compris l'insertion de gènes.
La présentation, intitulée 'Insertion homologue dirigée à haute efficacité dans le génome en utilisant des endonucléases de homing ingénierisées', sera délivrée par le Dr. Adam Mischler, Scientifique Senior chez Precision BioSciences Gene Discovery. Le poster (Numéro #PO678) sera présenté jeudi 24 octobre 2024, de 18h00 à 19h30 CEST. Cette présentation met en lumière les avancées de Precision BioSciences dans la technologie d'édition génétique, en particulier dans le traitement des maladies où un gène défectueux nécessite l'expression d'une nouvelle séquence d'ADN.
Precision BioSciences (Nasdaq: DTIL), ein fortschrittliches Unternehmen für Genbearbeitung, hat eine Posterpräsentation auf dem 31. Jahreskongress der Europäischen Gesellschaft für Gen- und Zelltherapie (ESGCT) in Rom, Italien, vom 22. bis 25. Oktober 2024 angekündigt. Das Unternehmen nutzt seine proprietäre ARCUS®-Plattform, um in-vivo-Gentherapien für anspruchsvolle genetische Veränderungen, einschließlich Geninsertionen, zu entwickeln.
Die Präsentation mit dem Titel 'Hocheffiziente homologe zielgerichtete Insertion ins Genom unter Verwendung von konstruierten Homing-Endonukleasen' wird von Dr. Adam Mischler, Senior Scientist bei Precision BioSciences Gene Discovery, gehalten. Das Poster (Nummer #PO678) wird am Donnerstag, den 24. Oktober 2024, von 18:00 bis 19:30 Uhr CEST präsentiert. Diese Präsentation hebt die Fortschritte von Precision BioSciences in der Genbearbeitungstechnologie hervor, insbesondere im Hinblick auf Erkrankungen, bei denen ein defektes Gen die Expression einer neuen DNA-Sequenz erfordert.
- None.
- None.
Presentation Details:
Title: High-efficiency homology-directed insertion into the genome using engineered homing endonucleases
Poster Number: #PO678
Presenter: Adam Mischler, PhD, Senior Scientist, Precision BioSciences Gene Discovery
Date and Time: Thursday, October 24, 2024, 6:00-7:30pm CEST
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into a gene to cause expression/add function), elimination (removing a genome, e.g., viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016444782/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When and where is Precision BioSciences (DTIL) presenting at the ESGCT Congress?
What is the title of Precision BioSciences' (DTIL) presentation at the ESGCT Congress?
Who is presenting the poster for Precision BioSciences (DTIL) at the ESGCT Congress?
What is the poster number for Precision BioSciences' (DTIL) presentation at the ESGCT Congress?
What technology does Precision BioSciences (DTIL) use for gene editing?
